Australia markets open in 2 hours 10 minutes

Senseonics Holdings, Inc. (SENS)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.4625-0.0245 (-5.03%)
At close: 04:00PM EDT
0.4600 -0.00 (-0.54%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4870
Open0.4799
Bid0.4674 x 900
Ask0.4675 x 1400
Day's range0.4560 - 0.4864
52-week range0.3840 - 1.0500
Volume1,274,260
Avg. volume2,609,531
Market cap245.503M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024.

  • Business Wire

    Eversense® CGM System Receives iCGM Designation by the US FDA

    GERMANTOWN, Md. & PARSIPPANY, N.J., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA).

  • PR Newswire

    SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS

    Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen